Oral daily and intermittent ibandronate normalize bone turnover and significantly reduce vertebral fracture risk: Results from a large phase III study.

被引：0

作者：

Emkey, R

Recker, RR

Stakkestad, JA

Mahoney, P

Schimmer, RC

机构：

[1] Radiant Res, Wyomissing, PA USA

[2] Creighton Univ, Sch Med, Omaha, NE 68178 USA

[3] CECRO AS, Haugesund, Norway

[4] F Hoffmann La Roche Ltd, Basel, Switzerland

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S372 / S372

页数：1

共 50 条

[41] Risk factors for incidence of vertebral fracture in men and women: 25-year fellow-up results from the Framingham osteoporosis study.
Samelson, EJ
Hannan, MT
Felson, DT
Zhang, YQ
Genant, HK
Kiel, DP
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S147 - S147
[42] Beta-blocker use, bone mineral density and fracture risk in older women:: Results from the EPIDOS prospective study.
Levasseur, R
Dargent-Molina, P
Sabatier, JP
Marcelli, C
Bréart, G
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S455 - S455
[43] Oral ibandronate decreases markers of bone resorption to the same extent as intravenous (i.v.) zoledronic acid in patients with bone metastases from breast cancer:: Results from a comparative phase III trial
Body, J
Lichinitser, M
Tjulandin, S
Garnero, P
Bergström, B
BONE, 2005, 36 : S212 - S213
[44] ABALOPARATIDE-SC SIGNIFICANTLY REDUCES VERTEBRAL AND NONVERTEBRAL FRACTURES AND INCREASES BONE MINERAL DENSITY REGARDLESS OF BASELINE RISK: RESULTS FROM THE ACTIVE PHASE 3 CLINICALTRIAL
Fitzpatrick, L. A.
Hattersley, G.
Miller, P. D.
Hu, M.
Russo, L. A.
Riis, B. J.
Williams, G. C.
Cosman, F.
OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S50 - S50
[45] BONE MINERAL DENSITY INCREASES WITH MONTHLY IV IBANDRONATE INJECTIONS CONTRIBUTE TO ITS FRACTURE RISK REDUCTION IN PRIMARY OSTEOPOROSIS: 3-YEAR ANALYSIS OF THE PHASE III MOVER STUDY
Hagino, H.
Nakamura, T.
Ito, M.
Nakano, T.
Hashimoto, J.
Tobinai, M.
Mizunuma, H.
OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S592 - S593
[46] The association between changes in bone mineral density (BMD) and biochemical markers of bone turnover at 1 year with vertebral fracture risk at 3 years: Results from the multiple outcomes of raloxifene evaluation (MORE) trial
Sarkar, S
Crans, GG
Wong, M
Harper, KD
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S208 - S208
[47] Prediction of non-vertebral fracture risk in 5201 postmenopausal women by quantitative ultrasound of the calcaneus:: 36-month final results from the ECOSAP prospective study.
Díez-Pérez, A
González-Macías, J
Vila, J
Gómez-Martín, F
Guerrero, T
Rodríguez-Roca, G
Montero, JJ
Fortea, MA
Nieto, I
Arqueros, P
Marín, F
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S67 - S67
[48] The OsteoLaus Cohort Study Bone mineral density, micro-architecture score and vertebral fracture assessment extracted from a single DXA device in combination with clinical risk factors improve significantly the identification of women at high risk of fracture
Lamy, O.
Krieg, M. -A.
Stoll, D.
Aubry-Rozier, B.
Metzger, M.
Hans, D.
OSTEOLOGIE, 2012, 21 (02) : 77 - 82
[49] Bone Mineral Density Increases with Monthly i.v. Ibandronate Injections Contribute to its Fracture Risk Reduction in Primary Osteoporosis: 3-Year Analysis of the Phase III MOVER Study
Hagino, Hiroshi
Nakamura, Toshitaka
Ito, Masako
Nakano, Tetsuo
Hashimoto, Junko
Tobinai, Masato
Mizunuma, Hideki
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
[50] Prospective identification of postmenopausal osteoporotic women at high vertebral fracture risk by radiography, bone densitometry, quantitative ultrasound, and laboratory findings -: Results from the PIOS Study
Glüer, MG
Minne, HW
Glüer, CC
Lazarescu, AD
Pfeifer, M
Perschel, FH
Fitzner, R
Pollähne, W
Schlotthauer, T
Pospeschill, M
JOURNAL OF CLINICAL DENSITOMETRY, 2005, 8 (04) : 386 - 395

← 1 2 3 4 5 →